跳至主要内容
临床试验/NL-OMON51839
NL-OMON51839招募中不适用

Immune checkpoint inhibition associated cardiovascular adverse events in cancer patients - ITHACA

Academisch Medisch Centrum0 个研究点目标入组 214 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
214

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Adult male or female, age >=50 years
  • - Prior to start therapy
  • - Confirmed diagnosis of cancer:
  • - Treatment-naive advanced esophageal, gastric, or gastro-esophageal cancer
  • planned for first-line nivolumab or chemotherapy only or follow-up only after
  • - Treatment-naive advanced colorectal cancer planned for first-line
  • pembrolizumab or other systemic therapies
  • - Recurrent or metastatic head/neck squamous cell carcinoma with disease
  • progression during platinum-based chemotherapy who are planned for
  • pembrolizumab or other systemic therapies
  • - Non-small-cell lung carcinoma planned for pembrolizumab or durvalumab or
  • other systemic therapies
  • - Advanced renal cell carcinoma planned for first-line ipilimumab/nivolumab or
  • other systemic therapies
  • - Inresectible or advanced melanoma planned for ipilimumab/ nivolumab

排除标准

  • ICI therapy in previous 12 months;
  • Suspected or confirmed viral, fungal, or bacterial infectious disease;
  • Use of immunosuppressive therapy prior to ICI start;
  • Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2;
  • Known allergy to iodinated contrast agents;
  • Atrial fibrillation

研究者

相似试验